AZBio Members
05/17/2013Brain State Technologies - AZ Bio Company of the Year | 2012 Finalist
Brain State Technologies has a mission statement that is three words: To Help People. The corporate headquarters is based in Scottsdale, AZ and has nearly 200 providers in 18 countries that have helped over 50,000 people. Lee Gerdes is the Founder and CEO of Brain State Technologies® and the creator of the breakthrough neuro-technology Brainwave Optimization with Real-Time Balancing™, which helps people of all ages and conditions to overcome cognitive, emotional, and physical challenges and is transforming and likely saving lives all over the world. The firm and its process have been featured on ABC, FOX, CBS, OWN, People, The New York Times, USA Today, PARADE, The Arizona Republic, BrainWorld, Frontiers in Neuroscience, and more. Brain State offers a non-invasive process versus using drugs or surgery for a wide range of applications to overcome cognitive, emotional, and physical challenges including sleep disorders, alcoholism, meth addition, and PTSD. Their work has resulted in the largest relational database of brain patterns on planet Earth. Brain State’s patent-pending procedure compares over 48,000 brain frequencies and its patented Relational Sound (Wave Aid) program provides for ongoing process support. Committed to serving our veterans, the company offers pro bono services to soldiers with debilitating symptoms of PTSD.
Arizona Commerce Authority
05/17/2013AZ Innovation Challenge Video
The Arizona Innovation Challenge (AIC), powered by the Arizona Commerce Authority , awards the most money in the country for a technology commercialization challenge – $3 million ($1.5 million twice yearly) to the world’s most promising technology ventures. Awards range from $100,000 to $250,000 per company. The results? A big-time investment in the most talented entrepreneurs. Bringing to market products that are literally changing the way the world works. Driving wealth and job creation for the state of Arizona. Are you up for the Challenge?
AZBio Members
06/15/2013Northern Arizona Bioscience Road Map Report
Take a tour of the wealth of bioscience talent and assets in Flagstaff, AZ.
AZBio Members
05/17/2013Raymond L. Woosley, MD, PhD - 2012 AZBio Pioneer
Raymond L. Woosley earned a Ph.D. in Pharmacology from the University of Louisville and an M.D. from the University of Miami. He began his career as the first scientist in the US operations for Glaxo, now known as GlaxoSmithKline. Dr. Woosley specialized in Internal Medicine and Clinical Pharmacology at Vanderbilt University where he rose to the rank of Professor of Medicine. At Georgetown University he served as Chairman of the Department of Pharmacology and in 2000 was appointed Associate Dean for Clinical Research. In 2001 he became Vice President for Health Sciences at the University of Arizona and Dean of the College of Medicine. In January of 2005 he assumed the position of President of The Critical Path Institute (C-Path), a non-profit corporation formed by the Food and Drug Administration, SRI, International and the University of Arizona to accelerate the development of safe innovative medicines. Since 1999, he has directed one of seven federally-funded (Agency for Healthcare Research and Quality) Centers for Education and Research on Therapeutics (CERT).Under Dr. Woosley’s leadership, C-Path (the Critical Path Institute) orchestrated the acceleration of medical product development through a unique collaborative process among industry, academia, and the FDA. Our collaborations among 6 global consortia, 1000+scientists, and 41 companies has already produced these notable successes: First preclinical safety biomarkers (7) qualified by the FDA, EMA, and PMDA (the Japanese counterpart) First CDISC (Clinical Data Interchange Standards Consortium) therapeutic area data standard First and largest open database of CDISC aggregated clinical trial data for Alzheimer’s disease (6,100 patients and 22 clinical trials) Read more First drug-disease trial model & clinical trial simulation tool submitted and under review by the FDA First imaging biomarker for trial enrichment qualified by the EMA Dr. Woosley’s research has investigated the basic and clinical pharmacology of drugs for the treatment of arrhythmias and the cardiac toxicity of drugs, and has been published in over 260 publications. His research discovered the mechanism of the toxicity of the antihistamine Seldane®. He is the recipient of the Rawls-Palmer Award from the American Society of Clinical Pharmacology and Therapeutics for his contributions to medicine and the FDA Commissioner’s Special Citation for his work to advise the agency on the toxicity of dietary supplements containing ephedra. Dr. Woosley is a Past-President of the Association for Medical School Pharmacology and the American Society for Clinical Pharmacology and Therapeutics. He has served on numerous boards including the US Pharmacopeia. He is a member of the Biodesign Institute at Arizona State University. As a member of the University of Arizona’s Sarver Heart Center and Bio5 Institute, he conducts research on the prevention of adverse drug interactions.
AZBio Members
05/17/2013AHSC: Helping People Live Better Longer
The Arizona Health Sciences Center at the University of Arizona The Arizona Health Sciences Center (AHSC) at the University of Arizona is a network of health-related organizations and activities unique in the state and region. Arizona’s only academic health sciences center, AHSC is based on the campus of the University of Arizona in Tucson and maintains a growing presence on the Phoenix Biomedical Campus in downtown Phoenix. From these vantage points, AHSC reaches across the state of Arizona and well beyond its borders to provide health-care education, research, patient care and service for Arizonans and their neighbors today and for the future.
AZBio Members
10/19/2013Ventana: The Birth of a Life Changing Idea
Ventana Medical Systems, Inc., a Member of the Roche Group, is a global leader in tissue diagnostic innovations for anatomic pathology. This video reveals the true story of a quest to improve the standard of care for a single patient -- a quest that began a new era in cancer diagnostics. Discover how automated staining is empowering histology labs worldwide to deliver prompt, personalized diagnostic information.
AZBio Members
05/17/2013David S Alberts AZBio Pioneer
David S. Alberts, MD. Throughout his career, Dr. Alberts has focused on translational cancer prevention and treatment research. The emphasis of his laboratory-based and clinical research has been on the chemoprevention and treatment of such pervasive and potentially deadly diseases as cancers of the breast, colon, ovary, and skin. He has been the UA Cancer Center’s director since 2005. Under Dr. Alberts’ leadership the extensive research portfolio of The University of Arizona Cancer Center includes more than $60 million in annual research funding, including four large NCI interdisciplinary programs, and two Special Programs of Research Excellence, one in gastrointestinal cancers and one in lymphoma. Clinically, Dr. Alberts pioneered new treatments for advanced ovarian cancers, including in vitro tumor cell chemosensitivity testing for personalized medicine strategies, intraperitoneal chemotherapy , and maintenance chemotherapy. Presently, Dr. Alberts helps to coordinate Phase I and II and pharmacokinetic drug studies at The University of Arizona Cancer Center for molecularly-targeted chemopreventive agents. His laboratory research is concentrated on the evaluation of new surrogate endpoint biomarkers for cancer prevention trials with a special focus on precursor lesions for bladder, breast, colon, cervical, endometrial, ovarian, prostate, and skin cancers, using quantitative histopathology (i.e. karyometric) approaches. His NCI funded drug and diagnostics research has resulted in more than two dozen patents and the co-founding of five Arizona pharmaceutical and biotechnology companies.
AZBio Members
05/17/2013Jennifer Kehlet Barton, PhD, 2012 Bioscience Educator of the Year
Jennifer Kehlet Barton, Ph.D., Associate Vice President for Research and Professor, Biomedical Engineering at The University of Arizona was named the 2012 Michael A. Cusanovich Bioscience Educator of the Year by the Arizona Bioindustry Association. Dr. Barton was nominated by students, past and present with supporting nominations by her co-workers, and selected for this honor by an independent panel of judges from across the state of Arizona for her contributions to all aspects of bioscience education. They include her skill as a course instructor, her compassion and patience as a mentor and adviser to undergraduate and graduate students, her strategic leadership in creating a learning environment and career path for students via her development and leadership of the UA Biomedical Engineering Programs, her recent role as Assistant Director of the BIO5 Institute, and her participation with industry in a broad range of industry association and community groups.